Technical Analysis for ANIX - Anixa Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 4.08 -2.39% -0.10
ANIX closed down 2.39 percent on Monday, April 22, 2019, on 2.96 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ANIX trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -2.39%
Bollinger Band Squeeze Range Contraction -2.39%
BB Squeeze + Lower Band Touch Range Contraction -2.39%
BB Squeeze Started Range Contraction -2.39%

Older signals for ANIX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
Medicine Biotechnology Cancer Medical Specialties Clinical Medicine Solid Tumors Immune System Cancer Treatments Gene Therapy Leukemia Chimeric Antigen Receptor
Is ANIX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.86
52 Week Low 2.96
Average Volume 45,589
200-Day Moving Average 4.281
50-Day Moving Average 4.8011
20-Day Moving Average 4.399
10-Day Moving Average 4.31
Average True Range 0.1969
ADX 40.17
+DI 5.2649
-DI 27.2816
Chandelier Exit (Long, 3 ATRs ) 4.4893
Chandelier Exit (Short, 3 ATRs ) 4.5507
Upper Bollinger Band 4.6518
Lower Bollinger Band 4.1462
Percent B (%b) -0.13
BandWidth 11.493521
MACD Line -0.1616
MACD Signal Line -0.1425
MACD Histogram -0.0191
Fundamentals Value
Market Cap 61.69 Million
Num Shares 15.1 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -6.80
Price-to-Sales 51.61
Price-to-Book 5.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.43
Resistance 3 (R3) 4.42 4.31 4.37
Resistance 2 (R2) 4.31 4.22 4.31 4.35
Resistance 1 (R1) 4.19 4.16 4.14 4.20 4.33
Pivot Point 4.08 4.08 4.05 4.08 4.08
Support 1 (S1) 3.96 3.99 3.91 3.97 3.83
Support 2 (S2) 3.85 3.93 3.85 3.81
Support 3 (S3) 3.73 3.85 3.79
Support 4 (S4) 3.74